Manufacturing Considerations for Animal Health Products
Manufacturing veterinary drug products requires a specialized understanding of animal physiology, formulation requirements, and regulatory expectations. While human and veterinary pharmaceuticals share foundational Good Manufacturing Practices (GMP) and Quality by Design (QbD) principles, animal health products present unique challenges related to species diversity, excipient selection, food safety, and environmental impact.
In this issue of The Altascientist, we explore:
- Species-specific formulation strategies: How differences in animal physiology influence dosage forms, drug delivery, and controlled-release technologies.
- Navigating excipient restrictions: Key regulatory, safety, and formulation considerations when selecting excipients for veterinary drug products.
- Manufacturing process validation: A real-world case study demonstrating how process optimization and scientific investigation helped achieve consistent, commercial-scale manufacturing of an extended-release injectable suspension.
Manufacturing Considerations for Veterinary Drug Products
Human and veterinary drug products share many of the same manufacturing foundations, including quality systems, process validation, contamination control, and consistent product quality. However, veterinary manufacturing must account for a broader range of species, dosage forms, and intended uses.
Manufacturing facilities must maintain appropriate environmental controls, qualified equipment, cleaning validation, and cross-contamination controls. Depending on the product and its intended use, manufacturing strategies may also require specialized containment measures and validated approaches to microbiological control.
Understanding these requirements is essential to developing manufacturing processes that support product quality while meeting applicable regulatory expectations.
Species-Specific Formulation and Excipient Considerations
A successful veterinary formulation must account for the physiological and practical needs of its target species. Factors such as gastrointestinal structure, taste sensitivity, administration method, and feeding behavior can influence how a product is formulated and manufactured.
Monogastric species, including pigs, dogs, and cats, may require different approaches to palatability and administration. Taste-masked suspensions, flavored chewables, tablets, capsules, and multiparticulate formulations can help address species-specific dosing needs.
Long-acting injectables, biodegradable polymer microspheres, and medicated feed premixes provide additional formulation options, each with distinct manufacturing and quality considerations.
Altasciences’ Manufacturing Expertise
At Altasciences, our fully integrated CRO and CDMO model brings together extensive nonclinical research expertise and pharmaceutical formulation and manufacturing capabilities. This unique combination provides a deeper understanding of species-specific physiology, animal health requirements, and the complexities of veterinary drug manufacturing.
Our manufacturing capabilities include formulation development, analytical testing, and manufacturing from early development through commercialization. Our CDMO facility includes an analytical laboratory, an R&D formulations laboratory, multiple manufacturing suites, and a cGMP warehouse on a single campus. Segregated Grade C cleanrooms support potent compound handling, from formulation through commercial scale.
Explore all issues of The Altascientist in our Resource Center.